LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 199.50 +6.50 (+3.37%) As of 11:59 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Diaceutics Stock (LON:DXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Diaceutics alerts:Sign Up Key Stats Today's Range 193▼ 199.5050-Day Range 127▼ 19552-Week Range 125▼ 199.50Volume550,495 shsAverage Volume213,139 shsMarket Capitalization£169.30 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 215Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXRX Stock News HeadlinesDiaceutics to Unveil Half-Year 2026 Results and Step Up Investor OutreachSeptember 8, 2026 | tipranks.comDiaceutics issues new shares under incentive plans, updates total voting rightsSeptember 2, 2026 | tipranks.comA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.October 6 at 1:00 AM | Investors Alley (Ad)Diaceutics and PCC Launch NGS Study to Boost Confidence in Cancer DiagnosticsAugust 20, 2026 | tipranks.comDiaceutics boosts employee share incentives and updates total voting rightsAugust 4, 2026 | tipranks.comDiaceutics Issues Shares Under Employee Incentive Schemes in Latest Block Listing UpdateApril 7, 2026 | tipranks.comDiaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share CapitalApril 1, 2026 | tipranks.comDiaceutics Issues New Shares to Trust as PDMRs Participate in Incentive PlanFebruary 3, 2026 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 128 at the beginning of 2026. Since then, DXRX shares have increased by 55.9% and is now trading at GBX 199.50. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) released its earnings results on Tuesday, September, 22nd. The company reported ($3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative trailing twelve-month return on equity of 0.68%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Company Calendar Last Earnings9/22/2026Today10/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Price Target for DiaceuticsGBX 215 High Price TargetGBX 215 Low Price TargetGBX 215 Potential Upside/Downside+7.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX (0.32) Trailing P/E RatioN/A Forward P/E Ratio197.37 P/E GrowthN/ANet Income-£2.84 million Net Margins-0.66% Pretax MarginN/A Return on Equity-0.68% Return on Assets-6.06% Debt Debt-to-Equity Ratio5.40 Current Ratio2.55 Quick Ratio9.92 Sales & Book Value Annual Sales£41.33 million Price / Sales4.10 Cash FlowGBX 63.95 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book4.35Miscellaneous Outstanding Shares84,861,000Free FloatN/AMarket Cap£169.30 million OptionableNot Optionable Beta0.88 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (LON:DXRX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.